Stockscreener 앱 받기
1.94
6.01%
0.11
시간 외 거래:
1.82
-0.12
-6.19%
전일 마감가:
$1.83
열려 있는:
$1.8
하루 거래량:
200.69K
Relative Volume:
0.08
시가총액:
$8.14M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+18.29%
1개월 성능:
+65.81%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.7301
$1.98
1주일 범위
$1.7301
$2.80
52주 변동 폭
$0.77
$4.80
Polyrizon Ltd Stock (PLRZ) Company Profile
PLRZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
1.94 | 8.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Polyrizon Ltd 주식(PLRZ)의 최신 뉴스
Polyrizon (PLRZ) Stock Climbs After Patent Publication Update - Stocks Telegraph
Polyrizon Shares Rise After Publication of National Patent Application - MarketWatch
Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today? - Benzinga
Patents and new EV’s have these small caps perking - RagingBull
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies - The Manila Times
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
Full Stock Market News from 2024-12-21 - StockTitan
SPRC stock touches 52-week low at $0.21 amid sharp decline - Investing.com India
Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial - MSN
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs - The Manila Times
Polyrizon Strengthens Clinical Leadership Ahead of Key 2025 PL-14 Trial, Appoints Regulatory Expert - StockTitan
U.S. Stocks Drop Sharply with Losses Across Major Sectors, Amazon and American Express Lead Declines - mediahousepress
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com India
Nektar Therapeutics (NKTR) Stock Plummets Amidst Biotech Sector Decline - GuruFocus.com
TFSA: 3 Top TSX Stocks for Your $7,000 Contribution - Yahoo Canada Finance
Wall Street-Heavily Traded - WDRB
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Strategic DealSends Polyrizon (PLRZ) Shares To New Heights - Stocks Telegraph
Stellantis moves up launch of hybrid Ramcharger as EV demand cools - Yahoo Canada Finance
Polyrizon Shares Surge on Impending Clinical Trial - MarketWatch
What's Going On With Polyrizon Shares Wednesday?Polyrizon (NASDAQ:PLRZ) - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Biotechs and nuclear power for AI in play today 📈 - RagingBull
Artificial Intelligence (AI) News Live Feed - StockTitan
Polyrizon's Moving Forward with Expected 2025 Clinical TrialEntered Manufacturing Agreement for its PL-14 Allergy Blocker - The Manila Times
Polyrizon Partners with EU Manufacturing Giant for Novel Allergy Blocker Clinical Production - StockTitan
OPEC+ wary of renewed US oil output rise under Trump, sources say - Yahoo Canada Finance
Oil sags on soft Chinese spending, investor pause before US Fed rate move - Yahoo Canada Finance
Federal Reserve is likely to slow its rate cuts with inflation pressures still elevated - Yahoo Canada Finance
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES - Yahoo Canada Finance
Notre Dame Cathedral's reopening spectacle capped a stellar year for luxury house LVMH - Yahoo Canada Finance
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance - The Manila Times
Polyrizon Strengthens Leadership Team with Key Regulatory Affairs VP Appointment from Eurofins - StockTitan
What do we know about the mysterious drones reported flying over New Jersey? - Yahoo Canada Finance
3 No Brainer Tech Stocks to Buy With $500 Right Now - Yahoo Canada Finance
Polyrizon enters into manufacturing pact for CTM supply of PL-14 allergy blocker - TipRanks
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - The Manila Times
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker - The Bakersfield Californian
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - GlobeNewswire Inc.
Polyrizon Partners with Eurofins for Clinical Trial Manufacturing of PL-14 Allergy Blocker - StockTitan
Polyrizon Ltd.’s Quiet Period To End on December 9th (NASDAQ:PLRZ) - Defense World
Polyrizon Ltd (PLRZ) 재무 분석
Polyrizon Ltd (PLRZ)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.60%
2.24%
자본화:
|
볼륨(24시간):